United Therapeutics Co. (NASDAQ:UTHR) Director Judy D. Olian Sells 1,750 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now directly owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Trading Up 0.1 %

Shares of NASDAQ:UTHR opened at $400.87 on Wednesday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a market cap of $17.90 billion, a P/E ratio of 17.61, a P/E/G ratio of 1.17 and a beta of 0.56. The company has a 50 day moving average of $360.91 and a 200 day moving average of $325.71.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the business posted $5.38 earnings per share. The firm’s revenue was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the business. SG Americas Securities LLC raised its stake in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after buying an additional 4,100 shares during the last quarter. Comerica Bank raised its position in shares of United Therapeutics by 5.9% during the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after buying an additional 9,244 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of United Therapeutics during the 2nd quarter worth $15,959,000. Finally, QRG Capital Management Inc. grew its position in United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after acquiring an additional 1,692 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.